𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin

✍ Scribed by Y. Kuroda; H. Takashima; A. Ikeda; C. Endo; R. Neshige; R. Kakigi; H. Shibasaki


Book ID
104719120
Publisher
Springer
Year
1991
Tongue
English
Weight
525 KB
Volume
238
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

✦ Synopsis


Fourteen patients with HTLV-1-associated myelopathy were treated with high-dose intravenous gammaglobulin (IVGG). Ten received 10 g/day of IVGG and 4 received 400 mg/kg of body-weight/day of IVGG for 5 consecutive days. Improvement of spastic paraparesis was observed in 10 within 7 days of the commencement of IVGG. The therapeutic effects were sustained for more than 3 weeks in some patients. There were no side effects. Analysis of factors of relevance to the clinical improvement with IVGG showed that the beneficial response was preferentially found in patients having a high CSF titre of anti-HTLV-I antibodies, a high CSF IgG level and a marked brain MRI abnormality.


πŸ“œ SIMILAR VOLUMES


Sequence heterogeneity of HTLV-I provira
✍ Dr. Jun-ichi Kira; Yoshio Koyanagi; Takeshi Yamada; Yasuto Itoyama; Jun Tateishi πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 774 KB

The nucleotide sequence of human T-lymphotropic virus type I (HTLV-I) in central nervous system tissue was determined in 3 autopsy cases with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) and 1 seropositive carrier without HAM/TSP but with multiple sclerosis. All HAM/TSP samp